BCR and B-cell chronic lymphocytic leukemia: Using preclinical models, the authors showed that targeting CD70 with anti-CD70 antibodies in CLL altered BCR, CD40L, IL4, and TNFR signaling and delayed CLL disease progression, thus suggesting the use of anti-CD70 immunotherapy in combination therapies in CLL [158].